{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:04:53Z","timestamp":1776276293606,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhejiang Provincial Medical Science and Technology Plan Project","award":["2022KY419"],"award-info":[{"award-number":["2022KY419"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00228-025-03841-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T16:44:05Z","timestamp":1745340245000},"page":"1029-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Post-market safety profile and suicide\/self-injury risk signals of dextromethorphan\/bupropion: a real-world pharmacovigilance study"],"prefix":"10.1007","volume":"81","author":[{"given":"Lingjing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"3841_CR1","doi-asserted-by":"crossref","unstructured":"(2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9(2):137\u2013150","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"3841_CR2","unstructured":"(2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222"},{"key":"3841_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-clinpsy-072220-021440","volume":"18","author":"SM Monroe","year":"2022","unstructured":"Monroe SM, Harkness KL (2022) Major depression and its recurrences: life course matters. Annu Rev Clin Psychol 18:329\u2013357","journal-title":"Annu Rev Clin Psychol"},{"issue":"6","key":"3841_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40273-021-01041-6","volume":"39","author":"PE Greenberg","year":"2021","unstructured":"Greenberg PE, Sisitsky T (2021) Introduction to the special issue of pharmacoeconomics on major depressive disorders. Pharmacoeconomics 39(6):617","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3841_CR5","first-page":"36","volume":"107","author":"R Luxton","year":"2022","unstructured":"Luxton R, Kyriakopoulos M (2022) Depression in children and young people: identification and management NICE guidelines. Arch Dis Child Educ Pract Ed 107(1):36\u201338","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"2","key":"3841_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/wps.20767","volume":"19","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Lee Y (2020) Preventing suicide in the context of the COVID-19 pandemic. World Psychiatry 19(2):250\u2013251","journal-title":"World Psychiatry"},{"key":"3841_CR7","doi-asserted-by":"crossref","unstructured":"Herrman H, Patel V, Kieling C et al (2022) Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet 399(10328)","DOI":"10.1016\/S0140-6736(21)02141-3"},{"issue":"2","key":"3841_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2215-0366(21)00479-X","volume":"9","author":"L-Z Kong","year":"2022","unstructured":"Kong L-Z, Lai J-B, Hu S-H (2022) China initiates depression screening in children and adolescents. Lancet Psychiatry 9(2):107\u2013108","journal-title":"Lancet Psychiatry"},{"key":"3841_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.apha.2020.04.004","volume":"89","author":"PA Davoudian","year":"2020","unstructured":"Davoudian PA, Wilkinson ST (2020) Clinical overview of NMDA-R antagonists and clinical practice. Adv Pharmacol 89:103\u2013129","journal-title":"Adv Pharmacol"},{"issue":"5","key":"3841_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter ID, Park LT, Zarate CA (2021) Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs 35(5):527\u2013543","journal-title":"CNS Drugs"},{"issue":"2","key":"3841_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/ejn.14990","volume":"53","author":"K-G Schraut","year":"2021","unstructured":"Schraut K-G, Kalnytska O, Lamp D et al (2021) Loss of the psychiatric risk factor SLC6A15 is associated with increased metabolic functions in primary hippocampal neurons. Eur J Neurosci 53(2):390\u2013401","journal-title":"Eur J Neurosci"},{"key":"3841_CR12","doi-asserted-by":"crossref","unstructured":"Iosifescu DV, Jones A, O'Gorman C et al (2022) Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry 83(4)","DOI":"10.4088\/JCP.21m14345"},{"issue":"11","key":"3841_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-022-00968-4","volume":"36","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Dextromethorphan\/bupropion: first approval. CNS Drugs 36(11):1229\u20131238","journal-title":"CNS Drugs"},{"issue":"10","key":"3841_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-023-01032-5","volume":"37","author":"D Akbar","year":"2023","unstructured":"Akbar D, Rhee TG, Ceban F et al (2023) Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials. CNS Drugs 37(10):867\u2013881","journal-title":"CNS Drugs"},{"key":"3841_CR15","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","volume":"14","author":"Z Fang","year":"2023","unstructured":"Fang Z, Xu Z, Zhu W et al (2023) A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system. Front Pharmacol 14:1101861","journal-title":"Front Pharmacol"},{"issue":"3","key":"3841_CR16","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2023","unstructured":"Shu Y, Ding Y, He X et al (2023) Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med 12(3):3365\u20133375","journal-title":"Cancer Med"},{"issue":"6","key":"3841_CR17","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","volume":"6","author":"NE Omar","year":"2021","unstructured":"Omar NE, Fahmy Soliman AI, Eshra M et al (2021) Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). ESMO Open 6(6):100315","journal-title":"ESMO Open"},{"key":"3841_CR18","doi-asserted-by":"publisher","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","volume":"15","author":"B Zhao","year":"2024","unstructured":"Zhao B, Fu Y, Cui S et al (2024) A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system. Front Pharmacol 15:1333662","journal-title":"Front Pharmacol"},{"key":"3841_CR19","doi-asserted-by":"crossref","unstructured":"Kwan ATH, McIntyre RS (2024) The association between dextromethorphan\/bupropion with alcohol and substance misuse: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). CNS Spectr 1\u20135.","DOI":"10.1017\/S1092852924000415"},{"issue":"1","key":"3841_CR20","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen C, Zhou R, Fu F et al (2023) Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatry 66(1):e99","journal-title":"Eur Psychiatry"},{"issue":"8","key":"3841_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Raschi E, Poluzzi E et al (2024) The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin Drug Saf 23(8):981\u2013994","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"3841_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3841_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"3841_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"3841_CR25","doi-asserted-by":"crossref","unstructured":"DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous. Am Stat","DOI":"10.2307\/2686097"},{"issue":"7","key":"3841_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","volume":"179","author":"H Tabuteau","year":"2022","unstructured":"Tabuteau H, Jones A, Anderson A et al (2022) Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry 179(7):490\u2013499","journal-title":"Am J Psychiatry"},{"key":"3841_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","volume":"354","author":"R Lu","year":"2024","unstructured":"Lu R, Jiang Y, Du Z et al (2024) Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database. J Affect Disord 354:649\u2013655","journal-title":"J Affect Disord"},{"issue":"1","key":"3841_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12992-020-00601-3","volume":"16","author":"J Zhou","year":"2020","unstructured":"Zhou J, Yuan X, Qi H et al (2020) Prevalence of depression and its correlative factors among female adolescents in China during the coronavirus disease 2019 outbreak. Global Health 16(1):69","journal-title":"Global Health"},{"issue":"2","key":"3841_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S2215-0366(16)30263-2","volume":"4","author":"C Kuehner","year":"2017","unstructured":"Kuehner C (2017) Why is depression more common among women than among men? Lancet Psychiatry 4(2):146\u2013158","journal-title":"Lancet Psychiatry"},{"issue":"10161","key":"3841_CR30","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ (2018) Depression. Lancet 392(10161):2299\u20132312","journal-title":"Lancet"},{"issue":"11","key":"3841_CR31","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1111\/bcp.15430","volume":"88","author":"B Revol","year":"2022","unstructured":"Revol B, Lapeyre-Mestre M, Fouilh\u00e9 Sam-La\u00ef N et al (2022) Association between NMDAR antagonists, drug abuse and dependence: a disproportionality analysis from the WHO pharmacovigilance database. Br J Clin Pharmacol 88(11):4937\u20134940","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03841-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:02:18Z","timestamp":1749578538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03841-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3841"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03841-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The information, results, or interpretation of the current study do not represent any opinion of the FDA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This study does not require ethical approval to use the publicly available and anonymised datasets from the FAERS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}